| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Ninepoint BCE HighShares ETF declares 0.100000 dividend | ||
| Di | Thanksgiving leftovers no one wants: 10 worst S&P 500 stocks of 2025 | ||
| Di | Thanksgiving feast of gains: 10 best S&P 500 stocks of 2025 | ||
| Di | Virgin Galactic shares snap six-session losing streak | ||
| Di | TotalEnergies to relocate Le Havre FLNG terminal after French court ruling | ||
| Di | Bessent reaches final second-round interview for next Fed chair | ||
| Di | Ninepoint Barrick HighShares ETF declares CAD 0.13 dividend | ||
| Di | Ninepoint Balanced+ Fund declares CAD 0.0833 dividend | ||
| Di | TuSimple Holdings declares $0.55 dividend | ||
| Di | Ninepoint Global Infrastructure Fund declares CAD 0.075 dividend | ||
| Di | Market Voices: Fed chair search, DOJ eyes PE, home delistings climb | ||
| Di | Ninepoint Target Income Fund declares CAD 0.0831 dividend | ||
| Di | YieldMax Universe Fund of Option Income ETFs declares $0.1012 dividend | ||
| Di | YieldMax Magnificent 7 Fund of Option Income ETFs declares $0.1227 dividend | ||
| Di | Peloton's AI-powered equipment struggling to gain traction with consumers | ||
| Di | Ninepoint Energy Income Fund Series ETF declares $0.108150 dividend | ||
| Di | YieldMax Ultra Option Income Strategy ETF declares $0.0594 dividend | ||
| Di | Ninepoint Alternative Credit Opportunities Fund declares CAD 0.0719 dividend | ||
| Di | Venezuela taps Chevron for key feedstock after U.S. blocked Russian ship - Bloomberg | ||
| Di | Best Buy outlines $41.65B-$41.95B revenue target for fiscal 2026 amid marketplace and ad business ramp | ||
| Di | Anavex outlines EMA reexamination strategy and highlights blarcamesine's long-term cognitive benefit amid regulatory setbacks | ||
| Di | Worst performing Consumer Staples stocks year-to-date: SDOT, EDBL, and others | ||
| Di | YieldMax Nasdaq 100 0DTE Covered Call ETF declares $0.4191 dividend | ||
| Di | YieldMax Crypto Industry & Tech Portfolio Option Income ETF declares $0.3673 dividend | ||
| Di | Novo Nordisk's amycretin shows weight loss in diabetes patients in phase 2 trial |